Author of

• 13737

  +

  P1.07 - Poster Session/ Small Cell Lung Cancer (ID 221)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Small Cell Lung Cancer
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 13742

    +

    P1.07-005 - Paclitaxel and Irinotecan in Platinum Refractory/Resistant Small Cell Lung Cancer: Final Analisis of One Galician Lung Cancer Group Experience (ID 1441)

    09:30 - 09:30  |  Author(s): L. Cadavid Vieitez
    • Abstract

    Background:
    Patients with Small Cell Lung Cancer (SCLC) whose disease progresses during or shortly after treatment with platinum, have a poor prognosis. Paclitaxel (P) and irinotecan(I) have demonstrated activity both as monotherapy as in combination regimen for this neoplasm. We have previously presented data from our experience with this agents in patients with SCLC . Here, we present a final analysis of survival and security.
    
    Methods:
    We included patients with measurable disease that had progressed during or within six months of first-line chemotherapy based on platinum, with an Eastern Cooperative Oncology Group (ECOG) performance status <2, adequate liver, renal and bone marrow function. They were treated with (P): 75 mg/m2 and (I): 50 mg/m2, both drugs administered on days 1 and 8 of a 21 day cycle. Treatment was maintained until disease progression and/or unacceptable toxicity.
    
    Results:
    We included 50 patients with a mean age of 65 years (43-77) and with metastases in two or more locations in 39 of them (78%). A median of 4 cycles of treatment was administered and eight patients (16%) received six or more cycles. The main reason for discontinuation of chemotherapy was disease progression, observed in 22 patients (44%). Partial response was documented in 18 patients (36%), stable disease in 20 (40%) and disease progression in 7 (14%). There were five patients in whom it was not possible to evaluate response. The median progression free survival was 4.09 months (CI 95%: 2.13-6.05) and the median overall survival was 5.092 months (CI 95% 4.22 – 5.96). No treatment-related deaths were described. The clinical and hematologic toxicities most frequently observed were grade 1 and 2: asthenia (n:20; 40%), diarrhea (n:14; 28%), anorexia (n:12; 24%), alopecia (n:11; 22%), neutropenia (n:5; 10%) and anemia (n:4; 8%). There was one (2%) grade 4 and four (8%) grade 3 neutropenia. There were no cases of grade 4 clinical toxicity and there were 16 (32%) grade 3 : nine of diarrhea (18%), three of asthenia (6%), one of vomiting (2%), one of hiponatremia (2%), one hepatic (2%) and one hyperglycemia (2%).
    
    Conclusion:
    This (P) and (I) regimen is an effective and well tolerated option for this subgroup of very poor prognosis patients with SCLC.Future explorations using this therapeutic regimen are warranted.